Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Cancer Cell

Volumn 29, Issue 1, 2016, Pages 75-89

  Hayes, Tikvah K ^a   Neel, Nicole F ^a   Hu, Chaoxin ^b   Gautam, Prson ^c   Chenard, Melissa ^d   Long, Brian ^d   Aziz, Meraj ^e   Kassner, Michelle ^e   Bryant, Kirsten L ^a   Pierobon, Mariaelena ^f   Marayati, Raoud ^a   Kher, Swapnil ^a   George, Samuel D ^a   Xu, Mai ^i,j   Wang Gillam, Andrea ^i,j   Samatar, Ahmed A ^d,k   Maitra, Anirban ^b   Wennerberg, Krister ^c   Petricoin, Emanuel F ^f   Yin, Hongwei H ^e   Nelkin, Barry ^g   Cox, Adrienne D ^a,h   Yeh, Jen Jen ^a,h   Der, Channing J ^a,h   more..

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF HELSINKI   (Finland)

^d MERCK RESEARCH LABORATORIES   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f GEORGE MASON UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j USA   (United States)

^k TheraMet Biosciences   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZD 8186; DINACICLIB; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P16; SCH 772984; SELUMETINIB; SMALL INTERFERING RNA; ULIXERTINIB; UNCLASSIFIED DRUG; KRAS2 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DEATH; CONTROLLED STUDY; GENE LIBRARY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; SENESCENCE; SHORT COURSE THERAPY; ANIMAL; GENETICS; METABOLISM; PANCREAS TUMOR; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; PROTO-ONCOGENE PROTEINS P21(RAS); TIME;

EID: 84958891287     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.11.011     Document Type: Article

References (44)

1. Alagesan B., Contino G., Guimaraes A.R., Corcoran R.B., Deshpande V., Wojtkiewicz G.R., Hezel A.F., Wong K.K., Loda M., Weissleder R., et al. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin. Cancer Res. 2015, 21:396-404.
2. Bardeesy N., Aguirre A.J., Chu G.C., Cheng K.H., Lopez L.V., Hezel A.F., Feng B., Brennan C., Weissleder R., Mahmood U., et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc. Natl. Acad. Sci. USA 2006, 103:5947-5952.
3. Bonet C., Giuliano S., Ohanna M., Bille K., Allegra M., Lacour J.P., Bahadoran P., Rocchi S., Ballotti R., Bertolotto C. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J. Biol. Chem. 2012, 287:29887-29898.
4. Bryant K.L., Mancias J.D., Kimmelman A.C., Der C.J. KRAS: feeding pancreatic cancer proliferation. Trends Biochem. Sci. 2014, 39:91-100.
5. Caldwell M.E., DeNicola G.M., Martins C.P., Jacobetz M.A., Maitra A., Hruban R.H., Tuveson D.A. Cellular features of senescence during the evolution of human and murine ductal pancreatic cancer. Oncogene 2012, 31:1599-1608.
6. Campisi J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75:685-705.
7. Cox A.D., Fesik S.W., Kimmelman A.C., Luo J., Der C.J. Drugging the undruggable RAS: mission possible?. Nat. Rev. Drug Discov. 2014, 13:828-851.
8. Deschenes-Simard X., Gaumont-Leclerc M.F., Bourdeau V., Lessard F., Moiseeva O., Forest V., Igelmann S., Mallette F.A., Saba-El-Leil M.K., Meloche S., et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev. 2013, 27:900-915.
9. Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 2005, 17:215-224.
10. Duncan J.S., Whittle M.C., Nakamura K., Abell A.N., Midland A.A., Zawistowski J.S., Johnson N.L., Granger D.A., Jordan N.V., Darr D.B., et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012, 149:307-321.
11. Eser S., Reiff N., Messer M., Seidler B., Gottschalk K., Dobler M., Hieber M., Arbeiter A., Klein S., Kong B., et al. Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 2013, 23:406-420.
12. Farrell A.S., Sears R.C. MYC degradation. Cold Spring Harb. Perspect. Med. 2014, 4. 10.1101/cshperspect.a014365.
13. Feldmann G., Mishra A., Hong S.M., Bisht S., Strock C.J., Ball D.W., Goggins M., Maitra A., Nelkin B.D. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010, 70:4460-4469.
14. Feldmann G., Mishra A., Bisht S., Karikari C., Garrido-Laguna I., Rasheed Z., Ottenhof N.A., Dadon T., Alvarez H., Fendrich V., et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol. Ther. 2011, 12:598-609.
15. Germann U., Furey B., Roix J., Marklan W., Hoover R., Aronov A., Hale M., Chen G., Martinez-Botella G., Alargova R., et al. The selective ERK inhibitor BVD-523 is active models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research. Cancer Res. 2015, 75:4693.
16. Goetz E.M., Ghandi M., Treacy D.J., Wagle N., Garraway L.A. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res. 2014, 74:7079-7089.
17. Hancox U., Cosulich S., Hanson L., Trigwell C., Lenaghan C., Ellston R., Dry H., Crafter C., Barlaam B., Fitzek M., et al. Inhibition of PI3Kbeta signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. Mol. Cancer Ther. 2015, 14:48-58.
18. Hatzivassiliou G., Liu B., O'Brien C., Spoerke J.M., Hoeflich K.P., Haverty P.M., Soriano R., Forrest W.F., Heldens S., Chen H., et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol. Cancer Ther. 2012, 11:1143-1154.
19. Hidalgo M., Amant F., Biankin A.V., Budinska E., Byrne A.T., Caldas C., Clarke R.B., de Jong S., Jonkers J., Maelandsmo G.M., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014, 4:998-1013.
20. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
21. Junttila M.R., Devasthali V., Cheng J.H., Castillo J., Metcalfe C., Clermont A.C., Otter D.D., Chan E., Bou-Reslan H., Cao T., et al. Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. Mol. Cancer Ther. 2015, 14:40-47.
22. Kapoor A., Yao W., Ying H., Hua S., Liewen A., Wang Q., Zhong Y., Wu C.J., Sadanandam A., Hu B., et al. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell 2014, 158:185-197.
23. Lim K.H., O'Hayer K., Adam S.J., Kendall S.D., Campbell P.M., Der C.J., Counter C.M. Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr. Biol. 2006, 16:2385-2394.
24. Liotta L.A., Espina V., Mehta A.I., Calvert V., Rosenblatt K., Geho D., Munson P.J., Young L., Wulfkuhle J., Petricoin E.F. Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003, 3:317-325.
25. Lito P., Rosen N., Solit D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 2013, 19:1401-1409.
26. Martz C.A., Ottina K.A., Singleton K.R., Jasper J.S., Wardell S.E., Peraza-Penton A., Anderson G.R., Winter P.S., Wang T., Alley H.M., et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci. Signal. 2014, 7:ra121.
27. Morris E.J., Jha S., Restaino C.R., Dayananth P., Zhu H., Cooper A., Carr D., Deng Y., Jin W., Black S., et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013, 3:742-750.
28. Nardella C., Clohessy J.G., Alimonti A., Pandolfi P.P. Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 2011, 11:503-511.
29. Nissan M.H., Rosen N., Solit D.B. ERK pathway inhibitors: how low should we go?. Cancer Discov. 2013, 3:719-721.
30. Ohtani N., Zebedee Z., Huot T.J., Stinson J.A., Sugimoto M., Ohashi Y., Sharrocks A.D., Peters G., Hara E. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001, 409:1067-1070.
31. Pemovska T., Kontro M., Yadav B., Edgren H., Eldfors S., Szwajda A., Almusa H., Bespalov M.M., Ellonen P., Elonen E., et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013, 3:1416-1429.
32. Samatar A.A., Poulikakos P.I. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat. Rev. Drug Discov. 2014, 13:928-942.
33. Shao D.D., Xue W., Krall E.B., Bhutkar A., Piccioni F., Wang X., Schinzel A.C., Sood S., Rosenbluh J., Kim J.W., et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014, 158:171-184.
34. Shimizu T., Tolcher A.W., Papadopoulos K.P., Beeram M., Rasco D.W., Smith L.S., Gunn S., Smetzer L., Mays T.A., Kaiser B., et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 2012, 18:2316-2325.
35. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., Settleman J. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
36. Stephen A.G., Esposito D., Bagni R.K., McCormick F. Dragging ras back in the ring. Cancer Cell 2014, 25:272-281.
37. Tolcher A.W., Khan K., Ong M., Banerji U., Papadimitrakopoulou V., Gandara D.R., Patnaik A., Baird R.D., Olmos D., Garrett C.R., et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin. Cancer Res. 2015, 21:739-748.
38. Villanueva J., Vultur A., Lee J.T., Somasundaram R., Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X., Gimotty P.A., Kee D., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
39. Vogel C.J., Smit M.A., Maddalo G., Possik P.A., Sparidans R.W., van der Burg S.H., Verdegaal E.M., Heck A.J., Samatar A.A., Beijnen J.H., et al. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK. Pigment Cell Melanoma Res. 2015, 28:307-317.
40. Waddell N., Pajic M., Patch A.M., Chang D.K., Kassahn K.S., Bailey P., Johns A.L., Miller D., Nones K., Quek K., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015, 518:495-501.
41. Wee S., Jagani Z., Xiang K.X., Loo A., Dorsch M., Yao Y.M., Sellers W.R., Lengauer C., Stegmeier F. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res. 2009, 69:4286-4293.
42. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl. Acad. Sci. USA 2007, 104:13028-13033.
43. Yeh E., Cunningham M., Arnold H., Chasse D., Monteith T., Ivaldi G., Hahn W.C., Stukenberg P.T., Shenolikar S., Uchida T., et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat. Cell Biol. 2004, 6:308-318.
44. Yoon S., Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006, 24:21-44.